The clinical performance is complex and often involves multi-systematic stresses. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. Treatment and management of myeloma require individual development, usually including drug therapy, rehabilitation interventions, and regular follow-up management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune diseases that have previously been difficult to treat have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to the changes in the course of treatment. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of myeloma. The platform serves the China International Medical Service System, a team of domestic and foreign experts with authority in the field of autoimmune and rheumatic immunity, to provide patients with the following services: 1.
Remote pre-diagnosis: Pre-examination of medical records, clear diagnostic directions and medical advice by a team of experts; 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.